IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

Autor:	Vis, M., Bos, W. H., Gerrit Jan Wolbink, Voskuyl, A. E., Twisk, J. W. R., Stadt, R., Hamann, D., Dijkmans, B. A. C., Lems, W. F.
Přispěvatelé:	Rheumatology, Epidemiology and Data Science, MOVE Research Institute, EMGO - Lifestyle, overweight and diabetes, CCA - Innovative therapy, Methodology and Applied Biostatistics, EMGO+ - Lifestyle, Overweight and Diabetes, Research Institute MOVE
Rok vydání:	2008
Zdroj:	Journal of Rheumatology, 35(3), 425-428. Journal of Rheumatology Scopus-Elsevier Vis, M, Bos, W H, Wolbink, G, Voskuijl, A E, Twisk, J W R, van de Stadt, R, Hamann, D, Dijkmans, B A C & Lems, W F 2008, ' IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis ', Journal of Rheumatology, vol. 35, no. 3, pp. 425-428 .
ISSN:	0315-162X
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::56a78c0d9ff2ccc60a48a9675fe6f7a3 https://research.vumc.nl/en/publications/4845bc05-aa58-4d93-a50f-64b680079d09 Zobrazit plný text záznamu